Novel Multi-Targeted Therapeutic Platforms • Nov. 6, 2019

Wednesday, Nov. 6, 2019
2 – 6:30 p.m.

Program Purpose

With the approval of the first bispecific T-cell engager in 2018, and with many more such multi-targeted antibodies in clinical trials, there has been a resurgence of interest in these multi-functional platforms. Other related platforms, such as cytokine fusions and CAR T cell approaches, are also making their mark on the cancer treatment landscape. As these agents make their way into the clinic, however, many important scientific and clinical questions have been raised. During this half-day program, multi-targeted therapeutic platforms will be discussed by experts in the field, along with the opportunity for investigators to submit their own related work for consideration at this unique symposium.

Intended Audience

The intended audience for this program includes, but is not limited to, basic, translational and clinical researchers; postdoctoral fellows; clinicians; and payers involved in cancer research from such affiliations as academia, industry and regulatory agencies.

Program Organizers

  • Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
  • Edward Cha, MD, PhD – Genentech
  • Leena Gandhi, MD, PhD – Eli Lilly
  • Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
  • Salil Patel, PhD – Bristol-Myers Squibb
  • Eric Rubin, MD – Merck & Co., Inc.

Educational Objectives

Upon completion of this meeting, participants will be able to:

  • Describe the different types of multi-targeted therapeutic platforms in preclinical and clinical studies.
  • Explain the similarities and differences between multi-targeted therapies and other immunotherapies in clinical use, such as adoptive cell therapies.
  • Understand the current state of clinical trials and approvals in cancer that employ multi-targeted therapeutic platforms.

SITC's Program: Novel Multi-Targeted Therapeutic Platforms is supported in part by grants from Bristol-Myers Squibb, Merck & Co., Inc. and Pfizer, Inc. (as of Sept. 13, 2019)

Presentation Application Submission

Applications for consideration to present during the Novel Multi-Targeted Therapeutic Platforms Pre-Conference Program were due by Aug. 1, 2019 at 5 p.m. PDT. 

Submission Criteria

Application reviewers consider a number of variables in reviewing and selecting the applications for presentation, including, but not limited to, the following criteria:
  • Content within your presentation application submission should be publicly available to present by Nov. 6, 2019.
Presentations should address one or more of the following topics:
  • Novel multi-targeted therapeutics in development for the treatment of cancer (antibodies, cytokine fusions, CAR Ts, etc.)
  • Combination therapies for the treatment of cancer that use a multi-targeted therapeutic
  • Studies of mechanisms of action of multi-targeted therapeutics, as well as response/resistance to these treatments
  • Investigation of other related scientific and clinical questions for multi-targeted therapeutics
Preference will be given to presentation application submissions with the following:
  • Has human models and clinical data
  • Has minimal overlap with other submitted presentations applications
  • Has not been presented elsewhere or have significant changes to the submission since last being presented or published

Program Schedule

Wednesday, Nov. 6, 2019

2 p.m.

Session 1: Basics of Multi-Targeted Therapeutic Platforms

2:05 – 4:15 p.m.

2:05 p.m. Overview of Different Platform Structures

2:25 p.m. Cytokine Fusions
Raphael Clynes, MD, PhD – Xencor, Inc.

2:45 p.m. Multi-Targeted CAR T cells
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

3:05 p.m. BiTEs, TriKEs, TriNKETs
Jeffrey S. Miller, MD – University of Minnesota

3:25 p.m. Break

3:40 p.m. Pros and Cons of Multi-Targeted Therapeutics Panel Discussion
Raphael Clynes, MD, PhD – Xencor, Inc.
David S. Hong, MD – The University of Texas MD Anderson Cancer Center
Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

Jeffrey S. Miller, MD – University of Minnesota

Session 2: Novel Platforms and Innovation

4:15 – 5:15 p.m.

4:15 p.m.
4:25 p.m.

4:35 p.m.
4:45 p.m.  
4:55 p.m.
5:05 p.m.
5:15 p.m.


Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms

Time: 5:30 - 6:25 p.m.

5:30 p.m.
Clinical Trial Designs

Angelo De Claro, MD – Food and Drug Administration
5:50 p.m.

Compare and Contrast with Cellular Therapies Panel Discussion
R. Angelo De Claro, MD – Food and Drug Administration

6:25 p.m. Closing

Schedule At-a-Glance

Wednesday, Nov. 6
World Immunotherapy Council's 3rd Young Investigator Symposium  
Novel Multi-Targeted Therapeutic Platforms
Thursday, Nov. 7

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity:
Early Career Scientist Networking Reception

Workshop on Intratumoral Immunomodulation

Meet-the-Expert Lunch
Grant Writing Workshop
34th Annual Meeting
Friday, Nov. 8 34th Annual Meeting Social Activity:
Poster Reception
Saturday, Nov. 9
34th Annual Meeting Social Activity:
Award Ceremony
Poster Reception
The Checkpoints Band Party
Sunday, Nov. 10 34th Annual Meeting Hot Topic Symposium